Compare ServiceNow Inc (NOW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

ServiceNow (NOW) trades at $131.11, down 7.19% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew from $7.2B in 2022 to $13.28B in 2025, though net income margin has fluctuated. Positive sentiment is driven by AI integration and conference presentations, while high valuation ratios like a P/E of 83.88 present risks.

The outlook remains positive due to robust revenue growth and AI-driven business expansion, but elevated valuations and competitive pressures warrant caution. Analyst consensus is strongly bullish with a $141.46 price target, though investors should monitor execution risks and macroeconomic headwinds that could impact future performance.

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.